Buy or sell Allogene Therapeutics stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

Allogene Therapeutics Stock

Allogene Therapeutics is a biotechnology company catalyzing cancer treatment through the development of CAR T therapy.

Headquarters

South San Francisco CA, US

Total Funding

$532M

About Allogene Therapeutics Stock

Allogene Therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor T-cell (CAR T) therapy directed at blood cancers and solid tumors. Allogeneic CAR T therapies are engineered from cells of healthy donors and stored for “off-the-shelf” use in patients. This approach eliminates the need to create personalized therapy from a patient’s own cells, simplifies manufacturing, and reduces the time patients must wait for CAR T treatment.

Funding History

April 2018$412M
September 2018$120M

Management

Chief Executive Officer and Co-Founder

David Chang

Other Companies

EquityZen does not have an affiliation with, formal relationship with, or endorsement from Allogene Therapeutics or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 70K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

LogoLogo